World Journal of Urology

, Volume 29, Issue 3, pp 355–360 | Cite as

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients

  • C. Seidel
  • M. Fenner
  • A. S. Merseburger
  • C. Reuter
  • P. Ivanyi
  • F. Länger
  • A. Ganser
  • V. Grünwald
Original Article



The tyrosine kinase inhibitor (TKI) sunitinib induces partial remissions (PR) in a substantial proportion of patients with metastatic renal cell carcinoma (mRCC). Only little is known about the activity of sunitinib in renal lesions in patients with metastatic disease, as most patients with synchronous metastases receive palliative nephrectomy.


Fourteen patients with clear cell mRCC with renal lesions and sunitinib therapy (50 mg OD, 4/2 scheme) were retrieved retrospectively from clinic records. Tumor assessment consisted of CT scans at least every two cycles, analyzed according to RECIST. In 5 of 14 patients, renal tumors were considered as the primary tumor, while the remaining patients had kidney metastases. In total, 65 target lesions were evaluated.


The median progression-free survival (PFS) of sunitinib was 8.7 months (range: 2.7–40.2). Median overall survival (OS) from initiation of TKI therapy was 26 months (range: 3–55). Best response according to RECIST consisted of partial remission (PR) in 4 patients, stable disease (SD) in 7 patients, a complete remission (CR) in 1 patient, and 2 patients with progressive disease (PD). Analyzing the response of renal lesions only, 1 patient had PD, 8 patients had SD, 4 patients had PR, and 1 had a CR. Palliative nephrectomy was performed after two courses of sunitinib in 2 patients.


In our cohort, similar responses of renal tumors and peripheral metastases were achieved with sunitinib treatment. Our results support the use of sunitinib to control renal tumor lesions in metastatic patients.


Sunitinib Renal cell carcinoma Renal lesions Primary RECIST 


  1. 1.
    Novick AC, Campbell SC (2002) Renal tumours. In: Walsh PC, Retik AB, Vaughan EDJ, Wein AJ (eds) Campbell’s urology. WB Saunders, Philadelphia, pp 2672–2772Google Scholar
  2. 2.
    Umed T, Niijima T (1986) Phase II study alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 58(6):1231CrossRefGoogle Scholar
  3. 3.
    Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659PubMedCrossRefGoogle Scholar
  4. 4.
    Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970PubMedCrossRefGoogle Scholar
  5. 5.
    Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedCrossRefGoogle Scholar
  6. 6.
    Fishman M, Seigne J (2002) Immunotherapy of metastatic renal cell cancer. Cancer Control 9:293–304PubMedGoogle Scholar
  7. 7.
    Pezaro C, Davis ID (2008) Targeted therapies in the treatment of renal cell carcinoma. Curr Med Chem 15(12):1166–1174PubMedCrossRefGoogle Scholar
  8. 8.
    Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7(6):645–656PubMedGoogle Scholar
  9. 9.
    Motzer RJHT, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(352):115–324PubMedCrossRefGoogle Scholar
  10. 10.
    van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14(8):2431–2436PubMedCrossRefGoogle Scholar
  11. 11.
    Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2):518–523PubMedCrossRefGoogle Scholar
  12. 12.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRefGoogle Scholar
  13. 13.
    Szczylik C, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee S, Carteni G, Hariharan S, Gore ME (2008) Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 (May 20 suppl): p abstr 5124Google Scholar
  14. 14.
    Wood L, Garcia JA, Elson P, Salas RN, Lane BR, Klein E, Stephenson A, Dreicer R, Campbell SC, Rini BI (2009) Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 27:15 s, (suppl; abstr 5096)Google Scholar
  15. 15.
    Wood CG, Margulis V (2009) Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115(10 Suppl):2355–2360PubMedCrossRefGoogle Scholar
  16. 16.
    Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076–4081PubMedCrossRefGoogle Scholar
  17. 17.
    Biswas S, Kelly J, Eisen T (2009) Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14(1):52–59PubMedCrossRefGoogle Scholar
  18. 18.
    Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. Mar 23. [Epub ahead of print]Google Scholar
  19. 19.
    Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068 Epub Jan 25 2010PubMedCrossRefGoogle Scholar
  20. 20.
    Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111PubMedCrossRefGoogle Scholar
  21. 21.
    Heng DY, Park T, Bjarnason GA, Vaishampayan UN, Tan M, Knox JJ, North SA, Kollmannsberger CK, Rini BI, Choueiri TK (2010) Progression-free survival (PFS) as a predictor of overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. ASCO Genitoruniary Cancers Symposium Abstract No. 329Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • C. Seidel
    • 1
  • M. Fenner
    • 1
  • A. S. Merseburger
    • 2
  • C. Reuter
    • 1
  • P. Ivanyi
    • 1
  • F. Länger
    • 3
  • A. Ganser
    • 1
  • V. Grünwald
    • 1
  1. 1.Department of Hematology, Hemostasis, Oncology and Stem Cell TransplantationHannover Medical SchoolHannoverGermany
  2. 2.Department of Urology and Urologic OncologyHannover Medical SchoolHannoverGermany
  3. 3.Institute of PathologyHannover Medical SchoolHannoverGermany

Personalised recommendations